Evidence map›Paper›PMID 35327746›Full record

ArticleChildren (Basel, Switzerland)2022

Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease.

Eduardo Castillo-Leon, Heather L Morris, Cheryl Schoen, Jacob Bilhartz, Patrick McKiernan, Tamir Miloh, Sirish Palle, Mohammad Nasser Kabbany, Breda Munoz, Andrea R Mospan and 4 more

Open access · goldAbstract read
In one paragraph

Article in Children (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Eduardo Castillo-LeonDepartment of Pediatrics, School of Medicine, Emory University, Atlanta, GA 30322, USA.
Heather L MorrisTarget RWE, Durham, NC 27703, USA.
Cheryl SchoenTarget RWE, Durham, NC 27703, USA.
Jacob BilhartzDepartment of Pediatrics, University of Michigan, Ann Arbor, MI 48109, USA.
Patrick McKiernanChildren's Hospital of Pittsburgh, Pittsburgh, PA 15224, USA.
Tamir MilohPediatric Gastroenterology, Pediatric Transplant Hepatology, Miami Transplant Institute, Miami, FL 33136, USA.
Sirish PalleDivision of Gastroenterology, OU Medicine, Oklahoma City, OK 73104, USA.
Mohammad Nasser KabbanyDepartment of Pediatric Gastroenterology, Hepatology, and Nutrition, Cleveland Clinic, Cleveland, OH 44195, USA.ORCID 0000-0001-5249-6894
Breda MunozTarget RWE, Durham, NC 27703, USA.
Andrea R MospanTarget RWE, Durham, NC 27703, USA.
Bryan RudolphThe Children's Hospital at Montefiore, The Pediatric Hospital for Albert Einstein College of Medicine, Bronx, NY 10467, USA.
Stavra A XanthakosDivision of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's, Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH 45229, USA.
Miriam B VosNutrition and Health Sciences Program, Laney Graduate School, Emory University, Atlanta, GA 30322, USA.
Target-Nash Investigators
Target (United States) · USEmory University · USAlbert Einstein College of Medicine · USChildren's Hospital of Pittsburgh · USCincinnati Children's Hospital Medical Center · USCleveland Clinic · USMiami Transplant Institute · USUniversity of Michigan · US

Funding

Biomarker Discovery for Nonalcoholic Fatty Liver Disease in ChildrenR01DK125701 · NIDDK · EMORY UNIVERSITY · PI VOS, MIRIAM B. · 2020 to 2022
$1.0M
NIDDK NIH HHS R01 DK125701TARGET PharmaSolutions Clinical trial number: NCT02815891
6 · The paper itself

Abstract

Background: Pediatric non-alcoholic fatty liver disease (NAFLD) is a major public health concern. Aminotransferase (ALT) is frequently used for screening and monitoring, but few studies have reported typical patterns of ALT elevation in children. Methods: TARGET-NASH is a real-world longitudinal observational cohort of patients with NAFLD receiving care across the United States. Analyses included children enrolled between 1 August 2016, and 12 October 2020, with at least one ALT measurement after enrollment. Peak ALT was based on the first and last available record and categorized into clinical cut points: <70 IU/L, >70−<250 IU/L, and >250 IU/L. A chi-squared test was used to compare differences in proportions, and a Kruskal−Wallis test was used to compare the medians and distributions of continuous responses. Results: Analyses included 660 children with a median age of 13 years. Of the 660, a total of 187 had undergone a biopsy and were more likely to be Hispanic or Latino (67% vs. 57%, p = 0.02) and to have cirrhosis (10% vs. 1%, p < 0.001). The highest ALT scores ranged from 28 U/L to 929 U/L; however, these scores varied across time. The prevalence of cirrhosis or any liver fibrosis stage was most common among children with a peak ALT > 70 U/L. Conclusions: Large variability was seen in ALT among children, including many values > 250 U/L. Higher levels of ALT were associated with increased prevalence of comorbidities and more advanced stages of NAFLD. These findings support an increased need for therapeutics and disease severity assessment in children with peak ALT > 70 U/L.

Indexed as

ALTcirrhosisnon-alcoholic fatty liver disease

Identifiers

PMID35327746
PMCPMC8946883
OpenAlexW4220914180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.